Clinical trial
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally…
NCT00075465 · GERCOR - Multidisciplinary Oncology Cooperative Group, Other · Unknown status
Key facts
| NCT number | NCT00075465 |
|---|---|
| Title | Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach |
| Official title | Phase II Study of Docetaxel and Epirubicine as First-Line Treatment in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach |
| Lead sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, epirubicin hydrochloride |
| Start date | Apr 1, 2001 |
| First posted | Jan 12, 2004 |
| Last update posted | Jul 24, 2008 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: